


In the Claims:

Please cancel claims 24, 26, 29 and 35-36 . Please amend claims 1, 22 and 23 as follows.

1. (Currently Amended) A compound of formula (I):



wherein:

R¹ is alkyl;

w is 0 or 1;

R¹¹ is H or C₁-₃alkyl;

Ring A is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

Ring B is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

a, b, c, f, g, and h are the same or different and are each independently 0 or 1;

d and j are the same or different and are independently 1 or 2;

each R² is the same or different and is independently selected from the group consisting of alkylene, alkenylene and alkynylene;

Y¹ and Y² are the same or different and are each independently selected from the group consisting of -O-, -S(O)ₓ- and -N(R⁵)-;

q is 0, 1 or 2;

each R³ and R⁴ are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, Het, -COR⁵, -CSR⁵, -CO₂R⁵, -COPh, -CO₂Ph, -C(O)Het, -C(O)NR⁵R⁶, -C(S)NR⁵R⁶, -C(=NR⁵)R⁶, -C(=NR⁵)NR⁵R⁶, -CR⁵=N-OR⁶, -OR⁵, -OCOR⁵, -S(O)ₚR⁵, -S(O)₂OH, -S(O)ₚNR⁵R⁶, -NR⁵R⁶, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁶, -NO₂, -CN, -SCN and -N₃;

each p is the same or different and is 0, 1 or 2;

m and n are the same or different and are each independently 0, 1, 2, 3, 4 or 5;  
each R<sup>5</sup> and each R<sup>6</sup> are the same or different and are each independently selected  
from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and  
cycloalkenyl;

Ph is phenyl optionally substituted by one or more substituents selected from the  
group consisting of halo, alkyl, -CO<sub>2</sub>R<sup>5</sup>, -OR<sup>5</sup>, -SO<sub>2</sub>R<sup>5</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup>, -  
R<sup>2</sup>-(NR<sup>5</sup>R<sup>6</sup>)CO<sub>2</sub>R<sup>5</sup>, Het, -R<sup>2</sup>-Het, -CN and -N<sub>3</sub>; and

Het is a monocyclic 5-6 membered heterocycle or heteroaryl group containing 1, 2 or  
3 heteroatoms selected from the group consisting of N, O and S optionally  
substituted by one or more substituents selected from the group consisting of  
halo, alkyl, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>6</sup>, -OR<sup>5</sup>, -SO<sub>2</sub>R<sup>5</sup>,  
-SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup>, oxo, -CN and -N<sub>3</sub>;

or a pharmaceutically acceptable salt, ~~solvate or physiologically functional derivative~~  
thereof.

2. (Original) The compound according to claim 1, wherein R<sup>1</sup> is methyl.
3. (Previously Presented) The compound according to claim 1, wherein  
Ring A is selected from the group consisting of aryl and 5-13 membered heteroaryl.
4. (Previously Presented) The compound according to claim 1, wherein  
Ring A is phenyl.
5. (Previously Presented) The compound according to claim 1, wherein  
Ring B is selected from the group consisting of phenyl, pyridine and pyrimidine.
6. (Previously Presented) The compound according to claim 1, wherein  
Ring B is phenyl.
7. (Previously Presented) The compound according to claim 1, wherein  
each R<sup>2</sup> is the same or different and is independently selected from the group  
consisting of alkylene and alkenylene.
8. (Previously Presented) The compound according to claim 1, wherein b  
is 0.

9. (Previously Presented) The compound according to claim 1, wherein b is 1 and Y<sup>1</sup> is selected from the group consisting of -O- and -N(R<sup>5</sup>)-.
10. (Previously Presented) The compound according to claim 1, wherein g is 0.
11. (Previously Presented) The compound according to claim 1, wherein g is 1 and Y<sup>2</sup> is -O-.
12. (Previously Presented) The compound according to claim 1, wherein d is 1.
13. (Previously Presented) The compound according to claim 1, wherein j is 1.
14. (Previously Presented) The compound according to claim 1, wherein each R<sup>3</sup> is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ph, Het, -COR<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, -COPh, -C(O)NR<sup>5</sup>R<sup>6</sup>, -OR<sup>5</sup>, -S(O)<sub>p</sub>R<sup>5</sup>, -S(O)<sub>p</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup>, -NO<sub>2</sub>, -CN and -N<sub>3</sub>.
15. (Previously Presented) The compound according to claim 1, wherein d is 1 and R<sup>3</sup> is selected from the group consisting of H, halo, alkyl, Ph, -COR<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, -COPh, -C(O)NR<sup>5</sup>R<sup>6</sup>, -OR<sup>5</sup>, -NR<sup>5</sup>R<sup>6</sup>, -NO<sub>2</sub> and -CN.
16. (Previously Presented) The compound according to claim 1, wherein each R<sup>4</sup> is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ph, Het, -COR<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>6</sup>, -OR<sup>5</sup>, -S(O)<sub>p</sub>R<sup>5</sup>, -S(O)<sub>2</sub>OH, -S(O)<sub>p</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>COR<sup>6</sup>, -NO<sub>2</sub> and -CN.
17. (Previously Presented) The compound according to claim 1, wherein j is 1 and R<sup>4</sup> is selected from the group consisting of H, halo, alkyl, -COR<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>6</sup>, -OR<sup>5</sup>, -S(O)<sub>p</sub>R<sup>5</sup>, -S(O)<sub>2</sub>OH, -S(O)<sub>p</sub>NR<sup>5</sup>R<sup>6</sup> and -NO<sub>2</sub>.
18. (Previously Presented) The compound according to claim 1, wherein m is 0, 1, 2 or 3.

19. (Previously Presented) The compound according to claim 1, wherein n is 1, 2, or 3.
20. (Previously Presented) The compound according to claim 1, wherein each R<sup>5</sup> and each R<sup>6</sup> are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl and cycloalkyl.
21. (Previously Presented) The compound according to claim 1, wherein each R<sup>5</sup> and each R<sup>6</sup> are the same or different and are each independently selected from the group consisting of H and alkyl.
22. (Currently Amended) A compound selected from the group consisting of:  
5-Methyl-7-phenyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-(2-nitrophenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(2-Bromophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(4-Fluorophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-[3-(trifluoromethyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
2,2-Dimethyl-*N*-(2-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)propanamide;  
2,2,2-Trifluoro-*N*-(2-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)acetamide;  
3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzonitrile;  
7-(3-Bromophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(3-Bromothiien-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(5-Bromopyridin-3-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

Methyl 3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzoate;  
 7-(5-Bromothien-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
 7-(3-Bromophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-methylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
 7-(3-Bromophenyl)-*N*-(3-chloro-4-morpholin-4-ylphenyl)-5-methylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
 3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzamide;  
 (2*E*)-3-{3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl}prop-2-enamide;  
 5-Methyl-*N*-(4-nitrophenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
 2-{3-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}ethanol;  
 4-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]benzene-sulfonamide;  
 7-(2-Methoxyphenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
 2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenol;  
 2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl acetate;  
 5-Methyl-7-[4-(trifluoromethyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-Methyl-*N'*-{4-[(5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}urea;  
 5-Methyl-7-phenyl-*N*-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
 (3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)(phenyl)methanone;  
 7-(1,3-Benzodioxol-5-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo-[5,1-*f*][1,2,4]triazin-2-amine;  
 Methyl 4-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzoate;  
 5-Methyl-7-(3-phenoxyphenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
 7-(3-Aminophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(1*H*-Indol-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(5-nitro-1*H*-pyrrol-2-yl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1*H*-pyrrol-2-yl)-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1*H*-indol-3-yl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Furyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(1*H*-Indol-5-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

2-[(2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)thio]benzonitrile;

5-Methyl-7-(2-[(3-(trifluoromethyl)phenyl)amino]phenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-quinolin-8-yl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzenesulfonamide;

*N*-Methyl-*N*'-[4-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]urea;

*N*-[4-Methoxy-3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

2-[3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]ethanol;

4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzenesulfonamide;

*N*-[4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

*N*-[3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

*tert*-Butyl 3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzylcarbamate;

4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenol;

5-Methyl-*N*-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

*N*-(5-Fluoro-2-methoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

*N*-{2-[4-Methoxy-3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl)amino)phenyl]ethyl}acetamide;

*N*-[5-(2-Aminoethyl)-2-methoxyphenyl]-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

*N*-(2,4-Dimethoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

*N*-(2,5-Dimethoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

Ethyl 5-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl)amino)nicotinate;

2-[3-({5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl)-ethanesulfonic acid;

5-Methyl-7-[3-(1*H*-pyrazol-4-ylethynyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

3'-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}-1,1'-biphenyl-3-carboxylic acid;

2-Amino-3-(3'-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}-1,1'-biphenyl-4-yl)propanoic acid;

5-Methyl-7-[2'-(trifluoromethyl)-1,1'-biphenyl-3-yl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

(2*Z*)-3-(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)-3-phenylprop-2-enamide;

7-[3-({5-(Ethylsulfonyl)-2-methoxyphenyl}amino)phenyl]-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-[3-({4-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl}amino)phenyl]-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-[3-({4-(1*H*-imidazol-1-yl)phenyl}amino)phenyl]-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-[3-[(3-Chloro-4-morpholin-4-yl)phenyl]amino]phenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

*N,N*-Dimethyl-1-{3-[(3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-  
f][1,2,4]triazin-7-yl}phenyl)amino]phenyl}-methanesulfonamide;  
5-Methyl-7-{3-[(4-{(4-methylpiperazin-1-yl)methyl}phenyl)-amino]phenyl}-*N*-(3,4,5-  
trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-Cyclopropyl-3-{3-[(3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-  
f][1,2,4]triazin-7-yl}phenyl)amino]benzenesulfonamide;  
7-(5-Bromo-2-thienyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-  
amine;  
7-(3-Bromo-2-thienyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-  
amine;  
5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(tetrahydro-2H-pyran-4-yl)imidazo[5,1-  
f][1,2,4]triazin-2-amine;  
5-Methyl-7-[2-(methyloxy)phenyl]-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-  
2-amine;  
5-Methyl-7-[3-(methyloxy)phenyl]-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-  
2-amine;  
7-(2-Chlorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-  
amine;  
5-Methyl-7-(1-methyl-1H-indol-3-yl)-*N*-[4-(methyloxy)phenyl]imidazo[5,1-  
f][1,2,4]triazin-2-amine;  
5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(1-phenylethyl)imidazo[5,1-*f*][1,2,4]triazin-2-  
amine;  
5-Methyl-7-(1-methyl-1H-indol-2-yl)-*N*-[4-(methyloxy)phenyl]imidazo[5,1-  
f][1,2,4]triazin-2-amine;  
5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(3-thienyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(3-Furanyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo-[5,1-*f*][1,2,4]triazin-2-amine;  
7-(2-Furanyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo-[5,1-*f*][1,2,4]triazin-2-amine;  
7-(4-Fluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-  
amine;  
5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(2-thienyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-Cyclopropyl-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-Cyclohexyl-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(2-Fluorophenyl)Fluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-  
f][1,2,4]triazin-2-amine;  
5-Methyl-*N*,7-bis[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;



5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(phenylmethyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(3-Fluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-Cyclohexyl-5-methyl-*N*-[3,4,5-tris(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(Cyclohexylmethyl)-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-[3,4-Bis(methyloxy)phenyl]-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-[3,5-Bis(methyloxy)phenyl]-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-{4-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}acetamide;  
5-Methyl-*N*-[4-(methylthio)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-{4-[[2-(Dimethylamino)ethyl]oxy]phenyl}-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-phenyl-*N*-(4-{[2-(1-piperidinyl)ethyl]-oxy}phenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-(3-{[2-(Dimethylamino)ethyl]oxy}phenyl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-(1-Acetyl-2,3-dihydro-1*H*-indol-5-yl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-Cyclohexyl-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-phenyl-*N*-(tetrahydro-2*H*-pyran-4-yl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-*N*-(4-{[2-(4-morpholinyl)ethyl]oxy}phenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-*N*-(3-{[2-(4-morpholinyl)ethyl]oxy}phenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-*N*-[4-(methyloxy)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-*N*,7-diphenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-*N*-[3-(methyloxy)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.

23. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

24. (Cancelled)

25. (Previously Presented) The pharmaceutical composition according to claim 23 further comprising a chemotherapeutic agent.

26. (Cancelled)

27. (Previously Presented) A method for the treatment of a neoplasm susceptible to Plk in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1.


28. (Original) The method according to claim 27, wherein said neoplasm is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, ovarian cancer, gastric carcinoma, pancreatic cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma.

29. (Cancelled)


30. (Previously Presented) A method for inhibiting proliferation of a cell, said method comprising contacting the cell with an amount of a compound according to claim 1 sufficient to inhibit proliferation of the cell, wherein said compound inhibits Plk.

31. (Previously Presented) A method for inhibiting mitosis in a cell, said method comprising administering to the cell an amount of a compound according to claim 1 sufficient to inhibit mitosis in the cell, wherein said compound inhibits Plk.


32. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising reacting a compound of formula (X):



33. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising reacting the compound of formula (XIII):



with a compound of formula (VI):



34. (Previously Presented) A process for preparing a compound according to claim 1 wherein:

Ring A is selected from the group consisting of cycloalkyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;


each R<sup>2</sup> is the same or different and is alkylene;

each R<sup>3</sup> and R<sup>4</sup> are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, Ph, Het, -OR<sup>5</sup>, -S(O)<sub>p</sub>R<sup>5</sup>, -S(O)<sub>2</sub>OH, -S(O)<sub>p</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup> and -NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>;


each R<sup>6</sup> and each R<sup>6</sup> are the same or different and are each independently selected from the group consisting of H, alkyl and cycloalkyl;

Ph is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, alkyl,  $-OR^5$ ,  $-SO_2R^5$ ,  $-SO_2NR^5R^6$ ,  $-NR^5R^6$ , Het, and  $-R^2$ -Het; and

Het is a monocyclic 5-6 membered heterocycle or heteroaryl group containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S optionally substituted by one or more substituents selected from the group consisting of halo, alkyl,  $-OR^5$ ,  $-SO_2R^5$ ,  $-SO_2NR^5R^6$ ,  $-NR^5R^6$  and oxo; and  
said process comprising coupling a compound of formula (XVIII):



with a compound of formula (XIX):



wherein X is Cl, Br, I or triflate.

35-36. (Cancelled)

37-46. (Cancelled)